ATS View
한국어

Pharmaceuticals Korean listed companies

Grouped by the industry code each company registered with DART. Sorted by latest quarterly operating profit.

한국어
Companies108
Operating profit₩657bnlatest quarter, combined
Operating losses35
Average dividend yield2.0%47 payers

There are 108 KOSPI and KOSDAQ companies classified under pharmaceuticals. Combined operating profit for the latest reported quarter across 103 of them was ₩657bn; 35 posted an operating loss and 9 swung to a profit from a loss a year earlier. The largest by quarterly operating profit were Hanmi Pharm, Daewoong and Daewoong Pharma. The median operating margin across the 100 with reported revenue was 3.8%. 47 paid a cash dividend, with an average reported yield of 2.0%.

Pharmaceuticals companies

CompanyLatest quarter op. profitDividend yieldArticles 30dSignals
Hanmi Pharm KOSPI₩131bn
+117% YoY		0.8%656Profit +50% Revenue & profit growth Op. margin 20%+ Share pledge Insider buying Clinical trial filing Dividend grower
Daewoong KOSPI₩76.6bn
-10% YoY		0.9%38–
Daewoong Pharma KOSPI₩68.1bn
+18% YoY		0.3%376Revenue & profit growth
Yuhan KOSPI₩66.9bn
+34% YoY		0.5%491Revenue & profit growth Insider buying Dividend grower
Oscotec KOSDAQ₩38.7bn–43Turnaround Revenue +30% Op. margin 20%+ Share pledge Stake purpose change Litigation
JW Pharmaceutical KOSPI₩33.3bn
+34% YoY		2.1%185Revenue & profit growth M&A / stake deal Dividend grower
HK inno.N KOSDAQ₩30.0bn
+54% YoY		0.8%183Profit +50% Major holder adding
Myungin Pharm KOSPI₩27.6bn
+10% YoY		2.1%5Op. margin 20%+ Dividend grower
DongKookPharmaceutical KOSDAQ₩26.1bn
+18% YoY		1.1%256Revenue & profit growth
Boryung KOSPI₩23.8bn
-6% YoY		1.7%57Treasury share sale M&A / stake deal
Huons Global KOSDAQ₩19.5bn
-23% YoY		1.6%4–
Celltrion Pharm KOSDAQ₩19.3bn
+24% YoY		0.3%6Revenue & profit growth
Chong Kun Dang Pharmaceutical KOSPI₩18.6bn
-21% YoY		0.6%121Share pledge Insider selling Insider buying New 5% holder Major holder adding Dividend cut
ST Pharm KOSDAQ₩18.3bn
+42% YoY		0.3%79Revenue +30% Revenue & profit growth Share pledge Clinical trial filing
Korea United Pharm KOSPI₩13.3bn
+24% YoY		3.1%49Dividend grower
Humedix KOSDAQ₩11.7bn
+8% YoY		2.3%123Op. margin 20%+ Dividend grower
Dongwha Pharm KOSPI₩10.3bn1.0%172Dividend cut
JW Lifescience KOSPI₩9.3bn
-0% YoY		–0–
Ahn-gook Pharmaceutical KOSDAQ₩8.6bn
+74% YoY		7.0%35Profit +50% Revenue & profit growth High dividend Dividend grower
L&C Bio KOSDAQ₩8.6bn0.1%146Turnaround Revenue +30% Op. margin 20%+ Share pledge Insider selling Insider buying Bonus issue
EuBiologics KOSDAQ₩8.6bn
-24% YoY		–42Op. margin 20%+ Clinical trial filing Supply contract
DaehanPharmaceutical KOSDAQ₩8.1bn
+4% YoY		3.3%1Insider buying Dividend grower
Whanin Pharm KOSPI₩7.9bn
+192% YoY		2.6%2Profit +50% Revenue & profit growth
Hana Pharm KOSPI₩7.3bn
+21% YoY		2.2%3Asset deal Dividend cut
Samjin Pharmaceutical KOSPI₩7.2bn
-10% YoY		3.9%123–
Chongkundang Holdings KOSPI₩6.6bn
-60% YoY		2.6%6Share pledge
Dong-a ST KOSPI₩6.3bn1.4%107Turnaround Clinical trial filing
Hanall Biopharma KOSPI₩5.6bn
+389% YoY		–85Profit +50% Insider selling
GC WellBeing KOSDAQ₩4.6bn
+10% YoY		1.5%3Revenue +30% Dividend grower
JIN Yang Pharmaceutical KOSDAQ₩4.2bn
+70% YoY		–1Profit +50%
RPbio KOSDAQ₩4.1bn
+76% YoY		10.0%5Profit +50% Revenue & profit growth High dividend
Sinsin Pharmaceutical KOSDAQ₩4.1bn
+83% YoY		1.4%2Profit +50% Revenue & profit growth
Yuyu Pharma KOSPI₩4.0bn
+78% YoY		2.5%74Profit +50%
CTC Bio KOSDAQ₩3.8bn
+67% YoY		–4Profit +50% Litigation
KyungdongPharm KOSDAQ₩3.7bn4.9%0Insider buying Major holder adding
Daebongls KOSDAQ₩3.7bn
+56% YoY		0.6%25Profit +50% Revenue & profit growth
JW Shinyak KOSDAQ₩3.6bn
+34% YoY		–3–
Sam Chun Dang Pharm KOSDAQ₩3.4bn0.0%92Turnaround Share pledge Supply contract Dividend cut
Dae Hwa Pharm KOSDAQ₩3.3bn–33Insider selling
Huons KOSDAQ₩2.9bn
-78% YoY		3.3%103–
Kwangdong Pharmaceutical KOSPI₩2.8bn
-38% YoY		1.1%187Major holder adding
Handok KOSPI₩2.8bn1.8%130Share pledge
Korean Drug KOSDAQ₩2.7bn
+19% YoY		4.1%4Revenue & profit growth Dividend grower
Theragen Etex KOSDAQ₩2.6bn–1Turnaround Insider selling
OPTUS Pharmaceutical KOSDAQ₩2.3bn
-25% YoY		–7–
Shinil Pharmaceutical KOSDAQ₩2.3bn
-29% YoY		3.0%0–
Korea Pharma KOSDAQ₩2.2bn–5Buyback
Daehan Nupharm KOSDAQ₩2.2bn
-30% YoY		1.4%1Share pledge
Kukje Pharma KOSPI₩2.1bn
-39% YoY		0.6%67Share pledge Insider selling Insider buying Control change
IL Dong Pharmaceutical KOSPI₩2.0bn0.6%81M&A / stake deal
DuChemBio KOSDAQ₩1.9bn
+2% YoY		–26–
Ildong Holdings KOSPI₩1.9bn0.9%0Turnaround
Sam-A Pharm KOSDAQ₩1.9bn
-7% YoY		–0–
PharmGen Science KOSPI₩1.8bn
-46% YoY		–17–
GC Biopharma KOSPI₩1.7bn
-94% YoY		–330–
Komipharm International KOSDAQ₩1.6bn
+1% YoY		–6Insider buying
Kukjeon KOSDAQ₩1.5bn–3Turnaround Share pledge Dilution risk Dividend cut
Bukwang Pharmaceutical IND KOSPI₩1.4bn
-30% YoY		3.3%139Revenue +30%
WooGeneB&G KOSDAQ₩1.4bn–1Major holder adding Insider buying
Withus Pharmaceutical KOSDAQ₩1.1bn–2–
Tdspharm KOSDAQ₩1.0bn–4–
Polaris AI Pharma KOSDAQ₩779m
-39% YoY		–0–
Samyang Biopharm KOSPI₩746m–29–
Cheil Bio KOSDAQ₩343m–0Turnaround
SunBio KOSDAQ₩284m–0–
Bcworldpharm KOSDAQ₩147m
-92% YoY		1.8%3–
Orientbio KOSPI₩50m–4Turnaround
DongKook Life Science KOSDAQ₩22m
-99% YoY		–31–
Daewon Pharmaceutical KOSPI−₩9m–201Clinical trial filing
ChoA Pharmaceutical KOSDAQ−₩23m–134 quarters of losses
Kyung Nam Pharm KOSDAQ−₩212m–19–
Pangen Biotech KOSDAQ−₩220m–1Swung to loss
Samik Pharm KOSDAQ−₩228m
-120% YoY		0.3%8Swung to loss Asset deal
Seoul Pharma KOSDAQ−₩343m–24 quarters of losses
Daesung Microbiological Labs KOSDAQ−₩472m1.0%0Swung to loss
Telcon RF Pharmaceutical KOSDAQ−₩806m–4Revenue +30% Supply contract
Myungmoon Pharm KOSPI−₩836m
-115% YoY		–0Swung to loss Insider buying
Hwail Pharm KOSDAQ−₩912m–1Swung to loss Dilution risk Private placement Control change
Union Korea Pharm KOSDAQ−₩1.3bn–31Dilution risk Private placement Capital reduction 4 quarters of losses
Yungjin Pharm KOSPI−₩1.5bn
-179% YoY		–14Swung to loss Supply contract
Ilsung IS KOSPI−₩1.6bn5.4%0High dividend 4 quarters of losses
Adbiotech KOSDAQ−₩1.9bn–8–
Vivozon Pharmaceutical KOSDAQ−₩1.9bn–1Share pledge 4 quarters of losses
Dongsung Pharmaceutical KOSPI−₩2.0bn–9Litigation
Keeps Biopharma KOSDAQ−₩2.4bn–5Revenue +30% Insider buying Share pledge Clinical trial filing
Cellbion KOSDAQ−₩2.6bn–8Clinical trial filing 4 quarters of losses
G2gbio KOSDAQ−₩2.7bn–794 quarters of losses
CMG Pharmaceutical KOSDAQ−₩3.0bn–22Insider selling Delisting / halt risk
FutureChem KOSDAQ−₩3.2bn–17Clinical trial filing 4 quarters of losses
S.Biomedics KOSDAQ−₩3.7bn–04 quarters of losses
Corestemchemon KOSDAQ−₩4.3bn–84 quarters of losses
Samsung Pharmaceutical KOSPI−₩5.0bn–1Clinical trial filing 4 quarters of losses
CKD Bio KOSPI−₩5.0bn
-274% YoY		–4Swung to loss Dividend cut
Samil Pharmaceutical KOSPI−₩6.3bn–20Share pledge Insider buying 4 quarters of losses
DongKoo Bio & Pharma KOSDAQ−₩6.5bn
-434% YoY		–30Swung to loss Share pledge
Ilyang Pharmaceutical KOSPI−₩6.8bn
-678% YoY		1.2%13Swung to loss
Reyon Pharmaceutical KOSPI−₩7.0bn–6Share pledge New 5% holder Major holder adding Dilution risk 4 quarters of losses
Jeil Pharmaceutical KOSPI−₩7.0bn
-250% YoY		–71Swung to loss
Shinpoong Pharmaceutical KOSPI−₩8.0bn
-263% YoY		–11Swung to loss Clinical trial filing
Binex KOSDAQ−₩9.2bn
-995% YoY		–10Swung to loss Share pledge
GeneOne Life Science KOSPI−₩12.8bn–13Litigation 4 quarters of losses
Aprogen Biologics KOSPI−₩17.5bn–0Revenue +30% Share pledge Major holder adding Insider buying 4 quarters of losses
Aprogen KOSPI−₩22.4bn–1Revenue +30% Major holder adding M&A / stake deal 4 quarters of losses
Hyundai Pharmaceutical KOSPI–0.3%54–
Poongjeon Pharmacy KOSDAQ––5Major holder adding Dilution risk Private placement 4 quarters of losses
Prestige Biologics KOSDAQ––5Split / consolidation 4 quarters of losses
Pharmaresearch Bio KONEX––3Insider selling
BASKHANBIOPharma KONEX––0–

Industry codes are the primary business each company registered with DART and may not reflect its full business mix. Figures come from DART filings; prices are not included. Not investment advice.